List view / Grid view
What can we learn from tumours after they stop responding to treatment? By studying patient tissue directly, researchers are finding new ADC targets that conventional screening often misses.
Scientists have developed an organ-on-a-chip platform that replicates age-related immune decline, offering a long-missing tool for testing cancer vaccines in older adults.
Researchers have discovered how renal medullary carcinoma cells evade immunotherapy by mimicking immune cells, driving rapid tumour progression.
Scientists have identified a little-known protein, FGD3, that can boost the power of key breast cancer treatments by helping drugs rupture tumour cells and activate the immune system.
With CD47 therapies constrained by safety, attention is turning to CD24 as a macrophage checkpoint target. Pheast’s PHST001 has now entered the clinic.
Take part in a live Q&A with oncology experts as they explore the scientific advances driving cancer drug discovery.
CAR T therapies are saving lives, but toxicities such as CRS and ICANS remain a major barrier. What will it take to overcome them?
Standard antibody therapies bind their target and trigger a response. But what if the real breakthrough is designing antibodies that first recognise context before they act? This article looks at how bispecifics are becoming smarter, more selective and more precise.
Immune resistance is one of cancer’s toughest tricks. By rethinking how we target GPCRs, scientists may finally have a way to modulate it with precision.
Find out how dual-target ADCs and tumour-specific Treg depletion are shaping the next wave of targeted cancer therapies.
Cytokine release syndrome (CRS) is a major barrier in cancer immunotherapy - but what if we could prevent it before it begins? Dr Liam Tremble, Principal Scientist at Poolbeg Pharma, discusses how POLB 001, an oral anti-inflammatory candidate, could offer a new way forward.
CatalYm announces new preclinical data showing that its clinical-stage antibody, visugromab, can overcome resistance to antibody-drug conjugates (ADCs), showing potential to restore anti-tumour immune responses in solid tumours.
Antibody-drug conjugates (ADCs) are transforming cancer therapy by enabling targeted drug delivery with minimised side effects, but their complex structure presents unique challenges in bioanalysis. This article explores cutting-edge strategies for optimising ADC evaluation, from quantifying drug-to-antibody ratios (DAR) to overcoming hurdles like payload interference and stability.
Claudia Zylberberg, Chair of Kosten Digital, reveals how AI is revolutionising cell and gene therapy, making drug discovery faster and more cost-effective.
Tubulis, led by CEO Dominik Schumacher, is advancing cancer treatment through next-generation antibody-drug conjugates (ADCs) designed to target solid tumours more effectively. Find out how the company is rapidly progressing its ADC pipeline to offer more precise and lasting treatment options for patients.
